Clinical Study

A Pilot Feasibility Study In The Detection And Monitoring Of Minimal Residual Disease In The Blood Of Patients Undergoing Treatment For High-Grade B Cell Lymphomas Including Diffuse Large B Cell Lymphoma (Dlbcl), C-Myc-Positive Dlbcl And Burkitt’S Ly

Posted Date: Sep 9, 2017

  • Investigator: John Morris
  • Specialties: Hematology/Oncology, Oncology, Cancer
  • Type of Study: Observational/Survey

The purpose of this research study is to learn how tumor cells can be detected from blood as a marker of the activity of your disease.


To Be Eligible To Participate, Patients Must Have Been Diagnosed With Diffuse Large B Cell No-Hodgkin's Lymphoma (Dlbcl Nhl), C-Myc-Positive Dlbcl Or Burkitt's Lymphoma


Lymphoma, Ucci-Hem-15-01, Hematologic Malignancy , Phase I, Diffuse Large B Cell Lymphoma

For More Information:

Uc Cancer Institute